These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38488653)

  • 1. Safety of bimekizumab over 3 years in patients with psoriasis.
    Br J Dermatol; 2024 Mar; 190(4):e38. PubMed ID: 38488653
    [No Abstract]   [Full Text] [Related]  

  • 2. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
    Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
    Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimekizumab for Moderate-to-Severe Plaque Psoriasis.
    Gotesman RD; Vender R
    Skin Therapy Lett; 2021 May; 26(3):1-4. PubMed ID: 34077151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab for psoriasis.
    Rodrigues MA; Freitas E; Torres T
    Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
    JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab for the Treatment of Psoriasis.
    Freitas E; Blauvelt A; Torres T
    Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials.
    Qiu Y; Zhu Y; Liu Y; Liu Q
    J Dermatolog Treat; 2023 Dec; 34(1):2199106. PubMed ID: 37010492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
    J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
    Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
    Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
    Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimekizumab (Bimzelx) for psoriasis.
    Med Lett Drugs Ther; 2024 Jan; 66(1694):11-13. PubMed ID: 38212257
    [No Abstract]   [Full Text] [Related]  

  • 19. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
    Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
    J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
    Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
    Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.